Please use this identifier to cite or link to this item:
Title: Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease.
Austin Authors: Chatterjee, Pratishtha;Pedrini, Steve;Stoops, Erik;Goozee, Kathryn;Villemagne, Victor L ;Asih, Prita R;Verberk, Inge M W;Dave, Preeti;Taddei, Kevin;Sohrabi, Hamid R;Zetterberg, Henrik;Blennow, Kaj;Teunissen, Charlotte E;Vanderstichele, Hugo M;Martins, Ralph N
Affiliation: Centre for Healthy Ageing, School of Psychology and Exercise Science, College of Science, Health, Engineering and Education, Murdoch University, Murdoch, WA, Australia
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom
UK Dementia Research Institute at UCL, London, UK
Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
KaRa Institute of Neurological Diseases, Macquarie Park, NSW, Australia
Anglicare, Castle Hill Sydney, NSW, Australia
School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA, Australia
The Cooperative Research Centre for Mental Health, Carlton South, Australia
Australian Alzheimer's Research Foundation, Nedlands, WA, Australia
ADx NeuroSciences, Gent, Belgium
Molecular Imaging and Therapy
Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Centers, Amsterdam, Netherlands
Biomarkable, Gent, Belgium
Issue Date: 11-Jan-2021
Date: 2021
Publication information: Translational Psychiatry 2021;11(1): 27
Abstract: Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in blood samples, and has been associated with Alzheimer's disease (AD). However, plasma GFAP has not been investigated in cognitively normal older adults at risk of AD, based on brain amyloid-β (Aβ) load. Cross-sectional analyses were carried out for plasma GFAP and plasma Aβ1-42/Aβ1-40 ratio, a blood-based marker associated with brain Aβ load, in participants (65-90 years) categorised into low (Aβ-, n = 63) and high (Aβ+, n = 33) brain Aβ load groups via Aβ positron emission tomography. Plasma GFAP, Aβ1-42, and Aβ1-40 were measured using the Single molecule array (Simoa) platform. Plasma GFAP levels were significantly higher (p < 0.00001), and plasma Aβ1-42/Aβ1-40 ratios were significantly lower (p < 0.005), in Aβ+ participants compared to Aβ- participants, adjusted for covariates age, sex, and apolipoprotein E-ε4 carriage. A receiver operating characteristic curve based on a logistic regression of the same covariates, the base model, distinguished Aβ+ from Aβ- (area under the curve, AUC = 0.78), but was outperformed when plasma GFAP was added to the base model (AUC = 0.91) and further improved with plasma Aβ1-42/Aβ1-40 ratio (AUC = 0.92). The current findings demonstrate that plasma GFAP levels are elevated in cognitively normal older adults at risk of AD. These observations suggest that astrocytic damage or activation begins from the pre-symptomatic stage of AD and is associated with brain Aβ load. Observations from the present study highlight the potential of plasma GFAP to contribute to a diagnostic blood biomarker panel (along with plasma Aβ1-42/Aβ1-40 ratios) for cognitively normal older adults at risk of AD.
DOI: 10.1038/s41398-020-01137-1
ORCID: 0000-0003-4877-1958
Journal: Translational Psychiatry
PubMed URL: 33431793
Type: Journal Article
Subjects: Alzheimer's disease
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
25666.pdf1.01 MBAdobe PDFThumbnail
Show full item record

Page view(s)

checked on Jul 15, 2024


checked on Jul 15, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.